Literature DB >> 23690187

Effect of hypericin on the ADAMTS-9 and ADAMTS-8 gene expression in MCF7 breast cancer cells.

Z Ocak1, M Acar, E Gunduz, M Gunduz, K Demircan, U Uyeturk, T Ozlü.   

Abstract

AIM: To investigate the effects of hypericin which is obtained from the plant Hypericum perforatum on the expression and the regulation of ADAMTS8 and ADAMTS9 genes in MCF7 breast cancer cells and on the viability of these cells.
MATERIALS AND METHODS: MCF7 cells were cultured and were separately exposed to 2, 10 and 50 µl/mL of hypericin. After 24 hours, RNA was isolated from these cells and converted to cDNA. The expression levels of ADAMTS8 and ADAMTS9 genes were evaluated using the Reverse Transcription Polymerase Chain Reaction. XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, disodium salt) cell viability assay was used to determine cytotoxicity.
RESULTS: ADAMTS9 expression in MCF7 cells were increased 1.8 and 3.6 fold with the use of 2 and 10 µl/mL of hypericin, respectively; and decreased 0.7 fold with the use of 50 µl/mL of hypericin. There was no significant change in the ADAMTS8 expression. Rapid cell death was observed in the cancer cells when hypericin was used at a dose of ≥ 50 µl/mL.
CONCLUSIONS: The increase in ADAMTS9 expression can be a useful factor in the prevention of possible metastasis in breast cancer and for the occurrence of a tumor suppressive effect. Hypericin increases the expression of ADAMTS9, therefore, it may show its antitumoral and antiapoptotic effects by means of ADAMTS9.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690187

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells.

Authors:  Jie Yao; Baosheng Zhou; Jian Zhang; Peiliang Geng; Kang Liu; Yunfeng Zhu; Weijie Zhu
Journal:  Tumour Biol       Date:  2014-05-15

Review 2.  The Function and Roles of ADAMTS-7 in Inflammatory Diseases.

Authors:  Yuying Zhang; Jiqiang Lin; Fanhua Wei
Journal:  Mediators Inflamm       Date:  2015-11-30       Impact factor: 4.711

3.  ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy.

Authors:  Maya Yasukawa; Yuexin Liu; Limei Hu; David Cogdell; Kshipra M Gharpure; Sunila Pradeep; Archana S Nagaraja; Anil K Sood; Wei Zhang
Journal:  Oncotarget       Date:  2016-08-08

4.  Hemoglobin stimulates the expression of ADAMTS-5 and ADAMTS-9 by synovial cells: a possible cause of articular cartilage damage after intra-articular hemorrhage.

Authors:  Takuya Tajima; Tomohisa Sekimoto; Nami Yamaguchi; Noboru Taniguchi; Syuji Kurogi; Masugi Maruyama; Etsuo Chosa
Journal:  BMC Musculoskelet Disord       Date:  2017-11-14       Impact factor: 2.362

5.  Upregulation of circ_0066444 promotes the proliferation, invasion, and migration of gastric cancer cells.

Authors:  Dawei Rong; Chaoxi Dong; Kai Fu; Hanjin Wang; Weiwei Tang; Hongyong Cao
Journal:  Onco Targets Ther       Date:  2018-05-11       Impact factor: 4.147

6.  ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation via Sequestering miR-301b-3p.

Authors:  Junqing Chen; Ling Cheng; Weibin Zou; Rong Wang; Xiaojia Wang; Zhanhong Chen
Journal:  Front Cell Dev Biol       Date:  2021-11-24

7.  The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.

Authors:  Bianfei Shao; Yixiao Feng; Hongbin Zhang; Fang Yu; Qianqian Li; Cui Tan; Hongying Xu; Jianming Ying; Lili Li; Dejuan Yang; Weiyan Peng; Jun Tang; Shuman Li; Guosheng Ren; Qian Tao; Tingxiu Xiang
Journal:  J Cell Mol Med       Date:  2017-11-29       Impact factor: 5.310

8.  Robust analysis of novel mRNA-lncRNA cross talk based on ceRNA hypothesis uncovers carcinogenic mechanism and promotes diagnostic accuracy in esophageal cancer.

Authors:  Li-Ping Chen; Hong Wang; Yi Zhang; Qiu-Xiang Chen; Tie-Su Lin; Zong-Qin Liu; Yang-Yang Zhou
Journal:  Cancer Manag Res       Date:  2018-12-27       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.